1225 Northmeadow Parkway
About StimLabs, LLCStimLabs, LLC, was founded in 2015 with a desire to advance the state of regenerative medicine. Within a year of its inception, StimLabs built and certified an ISO Class 7 clean room facility, conceptualized and launched a suite of amniotic-derived products, developed an extensive product pipeline across a range of clinical applications, and established a portfolio of intellectual property. StimLabs portfolio of products includes Ascent, a shelf-stable injectable amniotic fluid allograft, and Revita®, an intact human placental membrane allograft that preserves all layers of the native tissue in a shelf-stable format. These groundbreaking products apply to a wide range of clinical applications and provide a foundation on which StimLabs is developing new regenerative technologies at the intersection of pharmaceuticals, medical devices, and tissue transplants.
Founder & CEO: John Daniel
VP, Sales: Bob Milani
VP, Product Development: Sarah Griffiths Langbord PhD
VP, Quality Assurance & Regulatory Affairs: Melissa Gaynor O’Connor
Please click here for Stimlabs' products.
7 articles with StimLabs, LLC
StimLabs, a leader in regenerative technologies and products that are revolutionizing patient care, today announced the launch of Corplex P, a unique product solution to a common clinical need. Corplex P, a shelf
StimLabs, a leader in regenerative technologies and products that are revolutionizing patient care, today announced the launch of Corplex, the first of two umbilical cord derived products launching this year.
StimLabs Announces Enrollment of First Patient in Trial Investigating the Efficacy of Full-Thickness Human Placental Graft Revita® in Diabetic Foot Ulcers
First patient enrolled in StimLabs Revita Efficacy Trial for Diabetic Foot Ulcers
Both Revita and Ascent products are now much more accessible at both the Department of Veterans Affairs (VA) and the Department of Defense (DoD).
StimLabs Announces Enrollment of First Patient in Evaluating Efficacy of Full Thickness Placental Allograft, Revita®, in Lumbar Microdiscectomy Outcomes
StimLabs announced that the first patient has been enrolled in the company sponsored clinical trial assessing the safety and efficacy of Revita full thickness placental allograft placement following lumbar microdiscectomy procedures.